Alexion Pharmaceuticals (ALXN) said Monday that its newly approved drug Ultomiris achieved the primary goal of a late-stage clinical trial involving patients with a rare type of kidney disease.
Based on the successful outcome of the clinical trial, the Boston-based biotech will file a marketing application with regulators to expand the approved diseases covered by the Ultomiris label.
About the Author Reprints
